OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Schlechter on Updated Data for Botensilimab Plus Balstilimab in MSS mCRC

July 4th 2025

Benjamin L. Schlechter, MD, discusses efficayc and safety of botensilimab in combination with the anti–PD-1 antibody balstilimab in mCRC.

Dr Janjigian on PROs for Perioperative Durvalumab Plus FLOT in Gastric/GEJ Adenocarcinoma

July 4th 2025

Yelena Y. Janjigian, MD, discusses patient-reported outcomes and QOL assessments for durvalumab plus FLOT in resectable gastric/GEJ adenocarcinoma.

Dr O’Reilly on the Rapidly Evolving Role of Local Therapy in Metastatic Pancreatic Cancer

July 3rd 2025

Eileen M. O’Reilly, MD, discusses the rapidly evolving role of local therapy in the management of advanced/metastatic pancreatic cancer.

Dr Weinberg on the Efficacy of BXCL701 Plus Pembrolizumab in Pretreated, Metastatic PDAC

July 3rd 2025

Benjamin A. Weinberg, MD, FACP, discusses preliminary efficacy and safety findings from BXCL701 with pembrolizumab in microsatellite-stable mPDAC.

Dr Cheng on the Safety and Efficacy of Irpagratinib Plus Atezolizumab in Advanced HCC

July 3rd 2025

Qi Cheng, MD, discusses the safety and efficacy of irpagratinib plus atezolizumab in advanced hepatocellular carcinoma.

Dr Medina on the Long-Term Efficacy and Safety of Lifileucel TIL Therapy in Advanced Melanoma

July 3rd 2025

Theresa Medina, MD, discusses the long-term efficacy and safety of lifileucel TIL therapy in advanced melanoma.

Dr Cardoso on the Effect of Elinzanetant on Vasomotor Symptoms in HR+ Breast Cancer

July 3rd 2025

Fatima Cardoso, MD, MSc, FESMO, discusses the use of elinzanetant for vasomotor symptoms in women receiving endocrine therapy for HR+ breast cancer.

Dr Spigel on a 14-Gene Assay for Clarifying the Benefit of Adjuvant Chemo in NSCLC

July 2nd 2025

David Spigel, MD, discusses the potential clinical effect of a 14-gene molecular assay for identifying candidates for adjuvant chemotherapy in NSCLC.

Dr Daver on Initial Efficacy and Safety Data With Bexmarilimab Plus Azacitidine in Higher-Risk MDS

July 2nd 2025

Naval G. Daver, MD, discusses early efficacy and safety data for bexmarilimab plus azacitidine in patients with higher-risk myelodysplastic syndrome.

Dr Tarhini on Neoadjuvant Pembrolizumab Plus Vidutolimod in Resectable Melanoma

July 2nd 2025

Ahmad A. Tarhini, MD, PhD, discusses findings from the ECOG-ACRIN EA6194 trial of pembrolizumab plus vidutolimod in resectable melanoma.

Dr Bazhenova on the FDA Approval of Sunvozertinib for EGFR-Mutated mNSCLC

July 2nd 2025

Lyudmila A. Bazhenova, MD, discusses ways that sunvozertinib expands the treatment paradigm for EGFR-mutated metastatic non–small cell lung cancer.

Dr Riechelmann on the Management of Refractory Carcinoid Syndrome in Functional GI NETs

July 2nd 2025

Rachel Riechelmann, MD, PhD, discusses clinical guidance for the management of refractory carcinoid syndrome in functional GI neuroendocrine tumors.

Dr Raza on Early Safety and Efficacy Data With NXC-201 in AL Amyloidosis

July 1st 2025

Shahzad Raza, MD, shares preliminary data from the NEXICART-2 trial of NXC-201 in relapsed/refractory light chain amyloidosis.

Dr Kelly on Final OS and Long-Term DFS Benefit With Adjuvant Nivolumab After CRT in GEJ Cancer

July 1st 2025

Ronan J. Kelly, MD, expanded on data from the phase 3 CheckMate 577 study of adjuvant nivolumab following CRT in resected esophageal and GEJ cancer.

Dr Jani on the Inclusion of PRO End Points in Lung Cancer Clinical Trials

July 1st 2025

Chinmay Jani, MD, discusses the rate of inclusion of patient-reported outcome end points in clinical trials of patients with lung cancer.

Dr Uppaluri on the Implications of the FDA Approval of Perioperative Pembrolizumab in Resectable, Locally Advanced HNSCC

July 1st 2025

Ravindra Uppaluri, MD, PhD, discusses the FDA approval of pembrolizumab in the neoadjuvant and adjuvant setting for resectable, locally advanced HNSCC.

Dr Pothuri on Current Unmet Needs in Recurrent/Advanced Endometrial Cancer

July 1st 2025

Bhavana Pothuri, MD, discusses remaining unmet needs for patients with recurrent/advanced endometrial cancer.

Dr Vasquez on the Rationale for Investigating NAMPT Inhibition in Rhabdomyosarcoma

June 30th 2025

Juan Vasquez, MD, discussed unmet needs for patients with pediatric rhabdomyosarcoma that investigations of NAMPT inhibition may address.

Dr Mascarenhas on the Safety of Imetelstat Plus Ruxolitinib in Higher-Risk Myelofibrosis

June 30th 2025

John O. Mascarenhas, MD, discusses the safety profile of imetelstat plus ruxolitinib in patients with higher-risk myelofibrosis.

Dr Thaker on the Safety of IMNN-001 Plus Neoadjuvant Chemotherapy in Newly Diagnosed Ovarian Cancer

June 30th 2025

Premal H. Thaker, MD, MS, discusses the safety of intraperitoneal administration of IMNN-001 plus neoadjuvant chemotherapy in epithelial ovarian cancer.